BOTOX® is a simple, non-surgical procedure for temporarily reducing the appearance of moderate to severe facial lines – the vertical frown lines between the eyebrows that look like an “11” or “111”. BOTOX® reduces the activity of the muscles that cause the wrinkles to form by blocking nerve impulses that trigger wrinkle-causing muscle contractions, creating an improved appearance between the brows, forehead & crows feet (wrinkles around the eyes). Results begin in 3 to 7 days and can last from 2 to 4 months, individual results may vary.
XEOMIN® (incobotulinumtoxinA) is a prescription medication injected into muscles and used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
If you are an adult with moderate to severe glabellar lines, XEOMIN® may be right for you. Talk to Dr. Ver Hoeve to discuss the benefits and risks of treatment.
XEOMIN® contains botulinum toxin type A, a protein purified from the bacterium Clostridium botulinum.
How It Works
When you squint or frown, the muscles between your eyebrows contract, causing the skin to furrow and fold. Over time, as your skin ages and loses some of its elasticity, these repeated contractions can cause persistent frown lines.
Botulinum toxin type A – the active ingredient in XEOMIN®– acts on nerve endings in muscles to prevent muscle fibers from contracting. By reducing these contractions, XEOMIN® can temporarily reduce the lines between your eyebrows.
XEOMIN® was proven effective in two randomized, double-blind, multicenter, placebo-controlled clinical trials of 547 healthy, adult patients. The average age of patients in the study was 46 years. Patients received 20 Units of XEOMIN® and were classified as responders if they had a 2-grade improvement on a 4-point scale as assessed by the physician and patient. Using these criteria, treatment success was higher with XEOMIN® than placebo on Day 30 in both studies (60% and 48% vs. 0% for placebo in both studies). Based on these trials, XEOMIN® received FDA approval for use in glabellar lines in 2011.